Maryland, USA-based I-Mab (Nasdaq: IMAB) has announced a new clinical trial collaboration with cancer giant Bristol Myers Squibb (NYSE: BMY).
The partnership aims to evaluate givastomig, an investigational bispecific antibody, in combination with Opdivo (nivolumab) and chemotherapy, as a first-line treatment.
With Bristol Myers, I-Mab will test the combination as an option for advanced Claudin 18.2-positive gastric and esophageal cancers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze